{"prompt": "['Appendix 3:', \"Questionnaire to Determine the Participating Psychiatrists' Comfort with HCV Management\", 'Not at all comfortable', 'Somewhat comfortable', 'Comfortable', 'Very Comfortable', 'Counseling patients on', 'natural history of HCV', 'infection', 'Counseling patients on', 'benefits of treatment', 'Assessing fibrosis and', 'diagnosing cirrhosis', 'Counseling patients on', 'proper usage of', 'Epclusa', 'Counseling patients on', 'drug interactions with', 'Epclusa', 'Counseling patients on', 'efficacy of Epclusa', 'CRI 15-05 Protocol 13SEP2017', 'Page 49']['Appendix 4: GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities', 'Version 18June2012', 'HEMATOLOGY', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Hemoglobin', 'HIV POSITIVE', '8.5 to 10.0 g/dL', '7.5 to < 8.5 g/dL', '6.5 to < 7.5 g/dL', '< 6.5 g/dL', 'Adult and Pediatric 57 Days', '85 to 100 g/L', '75 to < 85 g/L', '65 to < 75 g/L', '< 65 g/L', 'HIV NEGATIVE', '10.0 to 10.9 g/dL', '9.0 to < 10.0 g/dL', '7.0 to < 9.0 g/dL', '< 7.0 g/dL', 'Adult and Pediatric 57 Days', '100 to 109 g/L', '90 to < 100 g/L', '70 to < 90 g/L', '< 70 g/L', 'OR', 'OR', 'OR', 'Any decrease from Baseline', 'Any decrease from Baseline', 'Any decrease from Baseline', '2.5 to < 3.5 g/dL', '3.5 to < 4.5 g/dL', '4.5 g/dL', '25 to < 35 g/L', '35 to < 45 g/L', '45 g/L', 'Infant, 36-56 Days', '8.5 to 9.4 g/dL', '7.0 to < 8.5 g/dL', '6.0 to < 7.0 g/dL', '< 6.0 g/dL', '(HIV POSITIVE OR', '85 to 94 g/L', '70 to < 85 g/L', '60 to < 70 g/L', '< 60 g/L', 'NEGATIVE)', 'Infant, 22-35 Days', '9.5 to 10.5 g/dL', '8.0 to < 9.5 g/dL', '7.0 to < 8.0 g/dL', '< 7.0 g/dL', '(HIV POSITIVE OR', '95 to 105 g/L', '80 to < 95 g/L', '70 to < 80 g/L', '< 70 g/L', 'NEGATIVE)', 'Infant, 1-21 Days', '12.0 to 13.0 g/dL', '10.0 to < 12.0 g/dL', '9.0 to < 10.0 g/dL', '< 9.0 g/dL', '(HIV POSITIVE OR', '120 to 130 g/L', '100 to < 120 g/L', '90 to < 100 g/L', '< 90 g/L', 'NEGATIVE)', 'CRI 15-05 Protocol 13SEP2017', 'Page 50']['HEMATOLOGY', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Absolute Neutrophil Count', '(ANC)', '1000 to 1300/mm', '3', '750 to < 1000/mm 3', '500 to < 750/mm\u00b2 3', '< 500/mmi', '3', 'Adult and Pediatric, > 7 Days', '1.00 to 1.30 GI/L', '0.75 to < 1.00 GI/L', '0.50 to < 0.75 GI/L', '< 0.50 GI/L', 'Infant, 2 - < 7 Days', '1250 to 1500/mm 3', '1000 to < 1250/mm\u00b2 3', '750 to < 1000/mm 3', '< 750/mm\u00b3', '1.25 to 1.50 GI/L', '1.00 to < 1.25 GI/L', '0.75 to < 1.00 GI/L', '< 0.75 GI/L', 'Infant, 1 Day', '4000 to 5000/mm', '3', '3000 to < 4000/mm\u00b3', '1500 to < 3000/mm 3', '< 1500/mm', '3', '4.00 to 5.00 GI/L', '3.00 to < 4.00 GI/L', '1.50 to < 3.00 GI/L', '< 1.50 GI/L', 'Absolute CD4+ Count', 'HIV NEGATIVE ONLY', 'Adult and Pediatric', '300 to 400/mmi', '3', '200 to < 300/mm\u00b3', '100 to < 200/mm\u00b3', '< 100/mm\u00b3', '> 13 Years', '300 to 400/L', '200 to < 300/L', '100 to < 200/L', '< 100/L', 'Absolute Lymphocyte Count', 'HIV NEGATIVE ONLY', 'Adult and Pediatric', '600 to 650/mm\u00b2 3', '500 to < 600/mm\u00b3', '350 to < 500/mm\u00b3', '< 350/mm\u00b3', '> 13 Years', '0.60 to 0.65 GI/L', '0.50 to < 0.60 GI/L', '0.35 to < 0.50 GI/L', '< 0.35 GI/L', 'Platelets', '100,000 to < 125,000/mm\u00b3', '50,000 to < 100,000/mm\u00b3', '25,000 to < 50,000/mm 3', '< 25,000/mm\u00b3', '100 to < 125 GI/L', '50 to < 100 GI/L', '25 to < 50 GI/L', '< 25 GI/L', 'WBCs', '2000/mm\u00b2 3 to 2500/mm\u00b3', '1,500 to < 2,000/mm 3', '1000 to < 1,500/mm\u00b3', '< 1000/mm\u00b3 3', '2.00 GI/L to 2.50 GI/L', '1.50 to < 2.00 GI/L', '1.00 to < 1.50 GI/L', '< 1.00 GI/L', 'Hypofibrinogenemia', '100 to 200 mg/dL', '75 to < 100 mg/dL', '50 to < 75 mg/dL', '< 50 mg/dL', '1.00 to 2.00 g/L', '0.75 to < 1.00 g/L', '0.50 to < 0.75 g/L', '< 0.50 g/L', 'CRI 15-05 Protocol 13SEP2017', 'Page 51']\n\n###\n\n", "completion": "END"}